Background: Adipokines and inflammatory markers contribute to the pathogenesis of T2D. This study investigated the impacts of T2D and different hypoglycemic agents on the important adipokines and inflammatory markers in newly diagnosed T2D patients.

Methods: The clinical parameters, leptin, adiponectin, resistin, fibroblast growth factor21, betatrophin, IL-1β and IFNγ were assessed in 41 normal-glucose controls and 416 newly diagnosed T2D patients. Then the patients were randomly assigned to receive exenatide, insulin or pioglitazone, with the above adipokines and inflammatory factors evaluated at 48 weeks.

Results: As shown in Table 1, compared with the controls, T2D patients had significantly higher IL-1β, lower leptin, adiponectin and IFNγ levels. Among the 416 patients, 342 patients completed the 48-week study. The HbA1c change (ΔHbA1c) were similar among groups. Exenatide significantly decreased the BMI and IL-1β, while increased IFNγ and adiponectin. Insulin markedly increased IL-1β and IFNγ. And pioglitazone only increased adiponectin. Multiple linear regression showed that Δleptin and Δadiponectin were associated with ΔBMI, but not with ΔHbA1c, fasting insulin or fasting C-peptide.

Conclusions: Exenatide has better impacts on improving IL-1β, IFNγ, and adiponectin levels than insulin and pioglitazone in T2D patients, which may probably due to decreasing BMI.


H. Deng: None. X. Yang: None. W. Xu: None. J. Lv: None. L. Zeng: None. B. Yao: None. J. Weng: None.


National Natural Science Foundation of China (81770821 to W.X.); National Key Research and Development Program of China (2016YFC1304801); Eli Lilly and Company

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at